Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar, +614

The Lancet Neurology

Multicentre StudyPharmacologyMedicineMyasthenia GravisNeuromuscular Blockade +1

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu, +213

The Lancet Neurology

MedicineGeneralised Myasthenia Gravis

Friedreich‐like ataxia with retinitis pigmentosa caused by the His¹⁰¹Gln mutation of the α‐Tocopherol transfer protein gene

Takanori Yokota, Toshiaki Shiojiri, Takanari Gotoda, +11

Annals of Neurology

GeneticsPathologyMolecular BiologyMolecular GeneticsDisease Gene Identification +15

Health‐related quality‐of‐life and treatment targets in myasthenia gravis

Kimiaki Utsugisawa, Shigeaki Suzuki, Yuriko Nagane, +9

Muscle & Nerve

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi, +562

Neurology

Early fast‐acting treatment strategy against generalized myasthenia gravis

Kimiaki Utsugisawa, Yuriko Nagane, Tetsuya Akaishi, +11

Muscle & Nerve

Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study

Yuriko Nagane, Hiroyuki Murai, Tomihiro Imai, +12

BMJ Open

The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome

Hiroyuki Murai, Kimiaki Utsugisawa, Masakatsu Motomura, +3

Clinical and Experimental Neuroimmunology

New GlsMedicinePharmacologyPediatricsClinical Trials +8

Relationship between dysphagia and depressive states in patients with Parkinson’s disease

Meng Han, Hirofumi Ohnishi, Michio Nonaka, +8

Parkinsonism & Related Disorders

Depressive StatesPsychiatryMood SymptomParkinson DiseaseParkinson ’ +8

Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double‐blind placebo‐controlled study in Japan

Kenji Sekiguchi, Nobuo Kohara, Masayuki Baba, +6

Journal of Diabetes Investigation